Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer’s disease
Alpha Cognition (NASDAQ: ACOG) has been granted a new patent by the USPTO titled 'Coated Tablets for pH-Dependent Release of Benzgalantamine.' The patent strengthens the company's intellectual property portfolio by protecting tablet formulations of benzgalantamine, extending ZUNVEYL's patent protection in the United States through 2044.
ZUNVEYL, a novel treatment for mild to moderate Alzheimer's disease, is designed to improve patient outcomes through optimized drug delivery. The company plans to launch ZUNVEYL in U.S. pharmacies in Q1 2025, where it will be available by prescription nationwide.
Alpha Cognition (NASDAQ: ACOG) ha ottenuto un nuovo brevetto dall'USPTO intitolato 'Compresse Rivestite per il Rilascio Dipendente dal pH della Benzgalantamina.' Il brevetto rafforza il portafoglio di proprietà intellettuale dell'azienda proteggendo le formulazioni di compresse di benzgalantamina, estendendo la protezione brevettuale di ZUNVEYL negli Stati Uniti fino al 2044.
ZUNVEYL, un trattamento innovativo per l'Alzheimer da lieve a moderato, è progettato per migliorare i risultati dei pazienti attraverso un'ottimizzazione della somministrazione del farmaco. L'azienda prevede di lanciare ZUNVEYL nelle farmacie statunitensi nel primo trimestre del 2025, dove sarà disponibile su prescrizione in tutto il paese.
Alpha Cognition (NASDAQ: ACOG) ha recibido una nueva patente de la USPTO titulada 'Tabletas Recubiertas para la Liberación Dependiente del pH de la Benzgalantamina.' La patente refuerza el portafolio de propiedad intelectual de la empresa al proteger las formulaciones de tabletas de benzgalantamina, extendiendo la protección de la patente de ZUNVEYL en Estados Unidos hasta 2044.
ZUNVEYL, un tratamiento novedoso para la enfermedad de Alzheimer leve a moderada, está diseñado para mejorar los resultados de los pacientes a través de una optimización en la entrega del medicamento. La empresa planea lanzar ZUNVEYL en farmacias de EE. UU. en el primer trimestre de 2025, donde estará disponible con receta en todo el país.
알파 코그니션 (NASDAQ: ACOG)은 'pH 의존성 벤즈갈란타민 방출을 위한 코팅된 정제'라는 제목의 새로운 특허를 USPTO로부터 부여받았습니다. 이 특허는 벤즈갈란타민의 정제 제형을 보호함으로써 회사의 지적 재산 포트폴리오를 강화하며, ZUNVEYL의 미국 내 특허 보호를 2044년까지 연장합니다.
ZUNVEYL은 경증에서 중등도의 알츠하이머병 치료를 위한 혁신적인 치료제로서, 최적화된 약물 전달을 통해 환자의 결과를 개선하도록 설계되었습니다. 회사는 2025년 1분기 중 미국 약국에서 ZUNVEYL을 출시할 계획이며, 전국에서 처방전을 통해 이용할 수 있게 됩니다.
Alpha Cognition (NASDAQ: ACOG) a obtenu un nouveau brevet de l'USPTO intitulé 'Comprimés Enrobés pour la Libération Dépendante du pH de la Benzgalantamine.' Ce brevet renforce le portefeuille de propriété intellectuelle de l'entreprise en protégeant les formulations de comprimés de benzgalantamine, prolongeant ainsi la protection par brevet de ZUNVEYL aux États-Unis jusqu'en 2044.
ZUNVEYL, un traitement novateur pour la maladie d'Alzheimer légère à modérée, est conçu pour améliorer les résultats des patients grâce à une optimisation de l'administration du médicament. L'entreprise prévoit de lancer ZUNVEYL dans les pharmacies américaines au premier trimestre 2025, où il sera disponible sur ordonnance à l'échelle nationale.
Alpha Cognition (NASDAQ: ACOG) hat vom USPTO ein neues Patent mit dem Titel 'Beschichtete Tabletten für die pH-abhängige Freisetzung von Benzgalantamin' erhalten. Das Patent stärkt das geistige Eigentum des Unternehmens, indem es die Tablettenformulierungen von Benzgalantamin schützt und den Patentschutz von ZUNVEYL in den Vereinigten Staaten bis 2044 verlängert.
ZUNVEYL, eine neuartige Behandlung für leichtes bis mittelschweres Alzheimer, wurde entwickelt, um die Patientenergebnisse durch optimierte Arzneimittelabgabe zu verbessern. Das Unternehmen plant, ZUNVEYL im ersten Quartal 2025 in amerikanischen Apotheken einzuführen, wo es landesweit auf Rezept erhältlich sein wird.
- Patent protection secured until 2044 for ZUNVEYL in the U.S. market
- Imminent commercial launch planned for Q1 2025
- Nationwide pharmacy distribution network confirmed
- None.
Insights
The newly granted patent for ZUNVEYL represents a significant strategic asset for Alpha Cognition, particularly given the timing ahead of its Q1 2025 commercial launch. The patent's coverage of pH-dependent release tablet formulations is technically sophisticated and commercially valuable for several reasons:
The extended protection through 2044 provides nearly 20 years of market exclusivity, which is important for pharmaceutical product lifecycle management and long-term revenue potential. The pH-dependent release technology suggests improved drug delivery optimization, potentially offering better bioavailability and reduced side effects compared to existing treatments.
From a market perspective, this patent strengthens Alpha Cognition's competitive position in the Alzheimer's treatment space, which is projected to grow substantially due to aging demographics. The composition patent specifically covering tablet formulations provides robust protection against potential generic competitors, typically more defensible than method-of-use patents.
The strategic value is further enhanced by:
- Immediate commercial relevance with the planned Q1 2025 launch
- Protection of the core delivery technology that differentiates ZUNVEYL
- Potential for premium pricing power due to proprietary formulation
- Enhanced ability to secure partnerships or licensing agreements
For investors, this patent approval materially de-risks the commercial prospects of ZUNVEYL by providing clear market exclusivity through 2044. With a market capitalization of
This newly issued patent strengthens Alpha Cognition’s intellectual property portfolio by covering the composition of tablet formulations of benzgalantamine, further reinforcing the Company’s existing patent protections. With this approval, ZUNVEYL has patent protection in
“This patent approval underscores the innovative nature of ZUNVEYL and enhances our ability to deliver a differentiated treatment option for patients with mild to moderate Alzheimer’s disease,” said Michael McFadden, CEO of Alpha Cognition. “The timing of this milestone is significant, as it coincides with our planned
ZUNVEYL represents a novel approach to symptomatic Alzheimer’s treatment, designed to improve patient outcomes through optimized drug delivery. ZUNVEYL will be available by prescription in pharmacies nationwide in Q1 2025.
About Alpha Cognition Inc.
Alpha Cognition Inc. is a clinical stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options.
For more information, please visit www.alphacognition.com.
Forward-looking Statements
This news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this news release may be a forward‐looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward‐looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. These forward-looking statements are subject to certain risks, including risks regarding our ability to raise sufficient capital to implement our plans to commercialize ZUNVEYL, risks regarding the efficacy and tolerability of ZUNVEYL, risks related to ongoing regulatory oversight on the safety of ZUNVEYL, risk related to market adoption of ZUNVEYL, risks related to the Company’s intellectual property in relation to ZUNVEYL, risks related to the commercial manufacturing, distribution, marketing and sale of ZUNVEYL, risks related to product liability and other risks as described in the Company’s filings with Canadian securities regulatory authorities and available at www.sedar.com and the Company’s filings with the United States Securities and Exchange Commission (the “SEC”), including those risk factors under the heading “Risk Factors” in the Company’s Form S-1/A registration statement as filed with the SEC on November 6, 2024 and available at www.sec.gov. These forward‐looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250212688224/en/
For further information:
Michael McFadden, CEO
Tel: 1-858-344-4375
info@alphacognition.com
https://www.alphacognition.com/
Source: Alpha Cognition Inc.
FAQ
When will ZUNVEYL (ACOG) be available in U.S. pharmacies?
How long is ZUNVEYL's patent protection extended for Alpha Cognition (ACOG)?
What is ZUNVEYL's target market for Alpha Cognition (ACOG)?
What type of patent did Alpha Cognition (ACOG) receive for ZUNVEYL?
